FirsthandHealth
medRxiv PreprintsInternational19 November 2026

Kidney Function Variability and Cardiovascular Outcomes in Heart Failure: Effects of Empagliflozin in the EMPEROR-Reduced Trial

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Background: Although sodium-glucose cotransporter-2 (SGLT2) inhibitors improve cardiovascular and kidney outcomes in patients with heart failure (HF), the prognostic significance of intraindividual kidney function variability and its modification by SGLT2 inhibition remain unclear. We investigated these relationships in patients with HF with reduced ejection fraction (HFrEF). Methods: This secondary analysis included 3,492 patients from the EMPEROR-Reduced trial. A location-scale joint model (LSJM) simultaneously evaluated the associations of estimated glomerular filtration rate (eGFR) levels,
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.